(Q38000337)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

1 reference

Laura Pouryamout

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Judith Dams

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Anja Neumann

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

789-802

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22480339%20AND%20SRC:MED&resulttype=core&format=json

Global prevalence of dementia: a Delphi consensus study

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Therapeutic approaches to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

The cost of dementia in Europe: a review of the evidence, and methodological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Systematic review of economic evaluations of Alzheimer's disease medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

A reevaluation of the duration of survival after the onset of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631830-000000000-00000

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22480339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22480339